Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
Sudhesh Kumar,
Momna Warraich,
Mahnoor Fatima,
Kristen McCullough,
Aref Al‐Kali,
Hassan B. Alkhateeb,
Kebede H. Begna,
Abhishek A. Mangaonkar,
Antoine N. Saliba,
Mark R. Litzow,
William Hogan,
Mithun Shah,
Mrinal M. Patnaik,
Animesh Pardanani,
Talha Badar,
James Foran,
Jeanne Palmer,
Cecilia Arana Yi,
Ayalew Tefferi,
Naseema Gangat American Journal of Hematology
· Wiley
· 2026-11-06
· DOI: 10.1002/ajh.70500
Аннотация
American Journal of Hematology, Volume 101, Issue 12, Page 2990-3000, December 2026.
Sudhesh Kumar, Momna Warraich, Mahnoor Fatima, Kristen McCullough, Aref Al‐Kali, Hassan B. Alkhateeb et al. Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients. // American Journal of Hematology. – 2026. – DOI: 10.1002/ajh.70500. – URL: https://onlinelibrary.wiley.com/doi/10.1002/ajh.70500?af=R
Sudhesh Kumar, Momna Warraich, Mahnoor Fatima, Kristen McCullough, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine N. Saliba, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, James Foran, Jeanne Palmer, Cecilia Arana Yi, Ayalew Tefferi, & Naseema Gangat (2026). Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients. American Journal of Hematology. https://doi.org/10.1002/ajh.70500
Sudhesh Kumar, et al. “Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients.” American Journal of Hematology, 2026. doi:10.1002/ajh.70500.
@article{Kumar2026,
title = {Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients},
author = {Kumar, Sudhesh and Warraich, Momna and Fatima, Mahnoor and McCullough, Kristen and Al‐Kali, Aref and Alkhateeb, Hassan B. and Begna, Kebede H. and Mangaonkar, Abhishek A. and Saliba, Antoine N. and Litzow, Mark R. and Hogan, William and Shah, Mithun and Patnaik, Mrinal M. and Pardanani, Animesh and Badar, Talha and Foran, James and Palmer, Jeanne and Yi, Cecilia Arana and Tefferi, Ayalew and Gangat, Naseema},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70500},
url = {https://onlinelibrary.wiley.com/doi/10.1002/ajh.70500?af=R}
}